Q-omics provides the consensus-scored DNM1P33 profile across patient tissues and cancer cell-line models. DNM1P33 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, DNM1P33 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, DNM1P33 RNA expression shows 8,065 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight UCEC, KIRC, and LIHC as cancer lineages where DNM1P33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNM1P33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNM1P33 survival associations across molecular data types. DNM1P33 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNM1P33 RNA expression–survival associations across cancer types. High DNM1P33 expression shows unfavorable associations in UCEC, DLBC, LIHC and KIRP, but favorable associations in UCS and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for DNM1P33 RNA expression.
This table summarizes DNM1P33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DNM1P33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNM1P33 shows lower tumor expression in BRCA, LUSC, KICH and LUAD and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher DNM1P33 RNA expression in tumor versus normal tissue (log2 FC = +0.119, t-test p < 0.001).
This table shows molecular features associated with DNM1P33 in patient tissues and cancer cell lines. In patient samples, DNM1P33 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
